Proceeds from the financing will be used to drive Obsidian's lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1030 Massachusetts Ave.
Cambridge, MA 02138
USA

Phone

(781) 806-6245

Website

www.obsidiantx.com

Email Address

[email protected]

Overview

Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients.

Profile

Social Media

Obsidian Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Paul Wotton

Chief Financial Officer

Ryan Daws

Chief Medical Officer

Gary Vanasse

Chief Scientific Officer

Jan ter Meulen

Vice President

Melanie Call

VP - Bus. Development

Kirsten Kester

VP - Finance

David Aubuchon

VP - Human Resources

Jennifer Peterson

VP - Manufacturing

Shyam Subramanian

Browse more venture capital transactions:

Prev: 9/13/2021: MaxRewards venture capital transaction
Next: 9/13/2021: Varo Money venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC transactions reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary